Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 10.17
(6.94%)
CNY 10.17
(6.94%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 621.02 Million CNY | 36.12% |
| 2022 | 456.23 Million CNY | 265.52% |
| 2021 | 124.81 Million CNY | 43.52% |
| 2020 | 86.97 Million CNY | -61.3% |
| 2019 | 224.74 Million CNY | 20.68% |
| 2018 | 186.23 Million CNY | 28.31% |
| 2017 | 145.14 Million CNY | 1.39% |
| 2016 | 143.15 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 775.66 Million CNY | 44.71% |
| 2024 Q1 | 638.69 Million CNY | 2.84% |
| 2024 Q2 | 536.02 Million CNY | -16.07% |
| 2023 Q3 | 620.21 Million CNY | 2.73% |
| 2023 Q4 | 621.02 Million CNY | 0.13% |
| 2023 FY | 621.02 Million CNY | 36.12% |
| 2023 Q1 | 495.28 Million CNY | 8.56% |
| 2023 Q2 | 603.73 Million CNY | 21.9% |
| 2022 Q4 | 456.23 Million CNY | 22.37% |
| 2022 Q3 | 372.83 Million CNY | 7.08% |
| 2022 Q2 | 348.18 Million CNY | 63.93% |
| 2022 FY | 456.23 Million CNY | 265.52% |
| 2022 Q1 | 212.4 Million CNY | 70.17% |
| 2021 Q4 | 124.81 Million CNY | 50.21% |
| 2021 Q3 | 83.09 Million CNY | -16.91% |
| 2021 Q2 | 100.01 Million CNY | 9.1% |
| 2021 Q1 | 91.67 Million CNY | 5.41% |
| 2021 FY | 124.81 Million CNY | 43.52% |
| 2020 Q2 | 127.43 Million CNY | -29.55% |
| 2020 FY | 86.97 Million CNY | -61.3% |
| 2020 Q4 | 86.97 Million CNY | 58.96% |
| 2020 Q3 | 54.71 Million CNY | -57.06% |
| 2020 Q1 | 180.87 Million CNY | -19.52% |
| 2019 Q4 | 224.74 Million CNY | 0.0% |
| 2019 FY | 224.74 Million CNY | 20.68% |
| 2019 Q2 | 217.08 Million CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 186.23 Million CNY | 28.31% |
| 2017 FY | 145.14 Million CNY | 1.39% |
| 2016 FY | 143.15 Million CNY | 0.0% |